Redefining the Undruggable Through Proximity
“Porem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.”
Armand Cognetta, founder and CEO of General Proximity, joins Bits in Bio to explore how proximity medicine is revolutionizing drug discovery by targeting proteins once considered impossible to drug.
They discuss the evolution beyond PROTACs, being a solo bio-founder in Y Combinator, and Armand's journey from imposter syndrome to raising $16M and winning a $3M ARPA-H grant.
From nearly running out of money to building breakthrough platform technology, Armand shares hard-won lessons on fundraising, team building, and maintaining startup speed in an industry known for decade-long timelines.
